<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03573232</url>
  </required_header>
  <id_info>
    <org_study_id>Università di Verona</org_study_id>
    <nct_id>NCT03573232</nct_id>
  </id_info>
  <brief_title>Prevalence of Abnormal Postures in Parkinson's Disease</brief_title>
  <acronym>POSTUREinPD</acronym>
  <official_title>Prevalence of Abnormal Postures in Parkinson's Disease: an Observational Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universita di Verona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universita di Verona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postural abnormalities represent disabling and painful complications in patients with
      Parkinson's disease (PD). The stooped posture is a typical feature of PD but with advancing
      of disease more severe body abnormalities can affect people with PD. These deformities
      include Pisa syndrome, camptocormia, antecollis, scoliosis and striatal deformities related
      to hand (striatal hand) and/or toes (striatal toes).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postural abnormalities represent disabling and painful complications in patients with
      Parkinson's disease (PD). The first postural trunk deviation in PD was first described by
      James Parkinson himself and recognized as stooped simian appearance, with flexion of the hips
      and knees, and rounding of the shoulders. Although the stooped posture is a typical feature,
      more severe spinal misalignment (and deformities) can affect people with PD. These postural
      deformities include Pisa syndrome (PS), camptocormia (CP), antecollis (AC), scoliosis (S) and
      striatal deformities related to hand (striatal hand) and/or toes (striatal toes). The
      prevalence of these postural deformities is variable because several diagnostic criteria have
      been used to characterize each deformity. Recently, a consensus of diagnostic criteria has
      been reached in literature permitting us to better mapping the presence of these deformities
      in people with PD.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 7, 2018</start_date>
  <completion_date type="Anticipated">October 7, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 7, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The prevalence of postural deformities</measure>
    <time_frame>1 day</time_frame>
    <description>% of people with Parkinson's disease reporting Pisa syndrome, camptocormia, antecollis, scoliosis and striatal deformities related to hand (striatal hand) and toes (striatal toes).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Data of birth</measure>
    <time_frame>1 day</time_frame>
    <description>(day/month/year);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sex</measure>
    <time_frame>1 day</time_frame>
    <description>(male/female)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>1 day</time_frame>
    <description>(score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPECIFIC EVALUATION FOR PATIENTS WITH PARKINSON'S DISEASE • Age at PD onset</measure>
    <time_frame>1 day</time_frame>
    <description>(years)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease duration of PD</measure>
    <time_frame>1 day</time_frame>
    <description>(years)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Hoehn and Yahr (H&amp;Y);</measure>
    <time_frame>1 day</time_frame>
    <description>Total score of Modified Hoehn and Yahr staging scale. It evaluates the stage of Parkinson's disease. Range= 1 to 5. Higher values represent worse stages of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale (UPDRS);</measure>
    <time_frame>1 day</time_frame>
    <description>The Unified Parkinson's Disease Rating Scale evaluates the motor and non-motor symptoms of Parkinson's disease. Range= 0 to 260. Higher values represent worse symptoms of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD phenotype</measure>
    <time_frame>1 day</time_frame>
    <description>(rigid acinetic; tremor; mixed type)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laterality of motor symptoms at PD onset</measure>
    <time_frame>1 day</time_frame>
    <description>(right, left, bilateral);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical asymmetry</measure>
    <time_frame>1 day</time_frame>
    <description>(number of patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by means of Parkinson's Disease Questionnaire-8;</measure>
    <time_frame>1 day</time_frame>
    <description>Parkinson's Disease Questionnaire-8 evaluates quality of life in patients with Parkinson's disease. Range= 0 to 100. Higher values represent worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Latency between PD onset and start of antiparkinsonian therapy</measure>
    <time_frame>1 day</time_frame>
    <description>(years)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacologic treatment at disease onset of PD</measure>
    <time_frame>1 day</time_frame>
    <description>(levodopa; dopaminoagonists; L-Dopa + dopaminoagonist; other therapies)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pharmacological therapy</measure>
    <time_frame>1 day</time_frame>
    <description>(levodopa; dopaminoagonists; L-Dopa + dopaminoagonist; other therapies)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levodopa equivalent daily dose</measure>
    <time_frame>1 day</time_frame>
    <description>(mg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of falls and direction</measure>
    <time_frame>1 day</time_frame>
    <description>(number, anterior, posterior, right, left)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbilities</measure>
    <time_frame>1 day</time_frame>
    <description>(heart diseases, malignancies, diabetes, hypertension, mental disorders, obesity, metabolic disorders, cerebrovascular diseases, physical trauma)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Associated medical conditions</measure>
    <time_frame>1 day</time_frame>
    <description>(osteoporosis, arthrosis, rheumatic diseases, otovestibular disorders)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS)</measure>
    <time_frame>1 day</time_frame>
    <description>Visual Analogue Scale evaluates pain intensity. Range= 0 to 10. Higher values represent higher pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPECIFIC EVALUATION FOR PATIENTS WITH ABNORMAL POSTURES Type of deformity</measure>
    <time_frame>1 day</time_frame>
    <description>(Pisa syndrome, camptocormia, anterocollis, scoliosis, striatal deformities)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degrees</measure>
    <time_frame>1 day</time_frame>
    <description>(wall goniometer and pictures with software-based analysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Latency to develop one or more postural deformity after PD onset</measure>
    <time_frame>1 day</time_frame>
    <description>(months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postural deformity duration</measure>
    <time_frame>1 day</time_frame>
    <description>(years)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pattern of postural deformity onset</measure>
    <time_frame>1 day</time_frame>
    <description>(acute, subacute, chronic)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postural deformity after drug modification</measure>
    <time_frame>1 day</time_frame>
    <description>(yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postural deformity awareness</measure>
    <time_frame>1 day</time_frame>
    <description>(yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head compensation</measure>
    <time_frame>1 day</time_frame>
    <description>(in case of PS, CP, AC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neck head on trunk angle</measure>
    <time_frame>1 day</time_frame>
    <description>(degrees)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neck tilt angle</measure>
    <time_frame>1 day</time_frame>
    <description>(degrees)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head tilt angle</measure>
    <time_frame>1 day</time_frame>
    <description>(degrees)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gaze angle (in case of AC)</measure>
    <time_frame>1 day</time_frame>
    <description>(degrees)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle and hip flexion (in case of CP)</measure>
    <time_frame>1 day</time_frame>
    <description>(degrees)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory trick</measure>
    <time_frame>1 day</time_frame>
    <description>(yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postural deformity direction only for PS</measure>
    <time_frame>1 day</time_frame>
    <description>(right/left)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The presence of metronome sign (in case of PS)</measure>
    <time_frame>1 day</time_frame>
    <description>(yes, no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side of PD symptoms at onset and PS inclination</measure>
    <time_frame>1 day</time_frame>
    <description>(ipsilateral, contralateral, bilateral)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side of PD symptoms at onset and hands/feet deformities</measure>
    <time_frame>1 day</time_frame>
    <description>(ipsilateral, contralateral, bilateral)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">794</enrollment>
  <condition>Parkinson Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        In the present multicenter study, consecutive outpatients with PD attending 7 movement
        disorders Italian tertiary centers (Verona, Ancona, Chieti, Pisa, Torino, Trieste, Roma)
        will be invited to participate. Participants will be considered enrolled after signing the
        consent form.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants will be considered enrolled after signing the consent form;

          2. Diagnosis of Parkinson's disease;

        Exclusion Criteria:

          1. Concomitant neurologic diseases known to negatively affect posture;

          2. A history of major spinal surgery or muscle and/or skeletal diseases;

          3. Treatment with drugs potentially able to induce abnormal postures;

          4. Clinical features consistent with a diagnosis of atypical parkinsonism;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Tinazzi, MD, PhD, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universita di Verona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicola Smania, MD, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Universita di Verona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marialuisa Gandolfi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universita di Verona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Geroin, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universita di Verona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michele Tinazzi, MD, PhD, Professor</last_name>
    <phone>0458124287</phone>
    <email>michele.tinazzi@univr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Geroin, PhD</last_name>
    <email>christian.geroin@univr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Experimental and Clinical Medicine - University &quot;Politecnica delle Marche&quot; Ancona -Italy. Neurorehabilitation Clinic - Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona.</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianna Capecci, MD, PhD</last_name>
      <email>m.capecci@univpm.it</email>
    </contact>
    <investigator>
      <last_name>Elisa Andrenelli, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neuroscience, Imaging and Clinical Sciences, University G.d'Annunzio of Chieti-Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Bonanni, MD, PhD</last_name>
      <email>l.bonanni@unich.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Ceravolo, MD, Professor</last_name>
      <email>r.ceravolo@med.unipi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele CTC Centro Parkinson Via della Pisana 235, 00163 Roma</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio Stocchi, MD</last_name>
      <email>fabrizio.stocchi@fastwebnet.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Neuroscienze A.O. Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Zibetti, MD</last_name>
      <email>maurizio.zibetti@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Neurologica, Dipartimento di Scienze Neurologiche, Chirurgiche e della Salute, Azienda Ospedaliera Universitaria integrata, Universita' di Trieste</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Manganotti, MD, PhD</last_name>
      <email>pmanganotti@units.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Tinazzi, MD, PhD, Professor</last_name>
      <email>michele.tinazzi@univr.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Doherty KM, van de Warrenburg BP, Peralta MC, Silveira-Moriyama L, Azulay JP, Gershanik OS, Bloem BR. Postural deformities in Parkinson's disease. Lancet Neurol. 2011 Jun;10(6):538-49. doi: 10.1016/S1474-4422(11)70067-9. Epub 2011 Apr 22. Review.</citation>
    <PMID>21514890</PMID>
  </reference>
  <reference>
    <citation>Tinazzi M, Geroin C, Gandolfi M, Smania N, Tamburin S, Morgante F, Fasano A. Pisa syndrome in Parkinson's disease: An integrated approach from pathophysiology to management. Mov Disord. 2016 Dec;31(12):1785-1795. doi: 10.1002/mds.26829. Epub 2016 Oct 25. Review.</citation>
    <PMID>27779784</PMID>
  </reference>
  <reference>
    <citation>Srivanitchapoom P, Hallett M. Camptocormia in Parkinson's disease: definition, epidemiology, pathogenesis and treatment modalities. J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):75-85. doi: 10.1136/jnnp-2014-310049. Epub 2015 Apr 20. Review.</citation>
    <PMID>25896683</PMID>
  </reference>
  <reference>
    <citation>Pandey S, Garg H. Postural &amp; striatal deformities in Parkinson`s disease: Are these rare? Indian J Med Res. 2016 Jan;143(1):11-7. doi: 10.4103/0971-5916.178577. Review.</citation>
    <PMID>26997007</PMID>
  </reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>May 7, 2018</study_first_submitted>
  <study_first_submitted_qc>June 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2018</study_first_posted>
  <last_update_submitted>July 14, 2018</last_update_submitted>
  <last_update_submitted_qc>July 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universita di Verona</investigator_affiliation>
    <investigator_full_name>Michele Tinazzi, MD, PhD</investigator_full_name>
    <investigator_title>M.D., Ph.D. Full Professor</investigator_title>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <keyword>Pisa Syndrome</keyword>
  <keyword>Camptocormia</keyword>
  <keyword>Antecollis</keyword>
  <keyword>Striatal deformities</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

